RETROSPECTIVE COMPARISON OF SAFETY AND EFFICACY OF BUCY AND HDM AS REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
(Abstract release date: 05/19/16)
EHA Library. Jin S. 06/09/16; 134890; PB1990
Prof. Dr. Song Jin
Contributions
Contributions
Abstract
Abstract: PB1990
Type: Publication Only
Background
Melphalan-based regimen is the standard regimen before autologous stem cell transplantation (ASCT) in the patients with multiple myeloma, but now melphalan is not on the China’s market. There were positive data reported in other researches in terms of safety, response rate and long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Aims
This study retrospectively compare the data in our single center on MM patients with busulfan (BU) and cyclophosphamide(CY) as regimen before ASCT form December to June 2013 to December 2014 with the high-dose melphalan (HDM) regimen. long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Methods
20 cases with BUCY and 17 cases with HDM regimen before ASCT in MM patients were compared in terms of incidence of adverse reaction, the rate of hematopoietic reconstitution, therapeutic effect evaluation and survival.
Results
There is no significant differences between age, gender, duration from diagnosis to transplantation, the type of disease and ISS stage, the number of cycles of induction chemotherapy and disease status before transplantation in the two groups. A 10-day of median myeloid hematopoietic recovery time was observed in both groups, and the median megakaryocyte hematopoiesis reconstruction time was 10-day and 11-day (P > 0.05), respectively, in BUCY and HDM group. The incidence of liver function injury above grade 2 in BUCY group was higher than that in HDM group (30% vs 0, P < 0.05), but there were no hepatic veno occlusive disease (VOD) occurs in both groups. And there was no significant difference in other all regimen toxicity, especially above grade 2 toxicity, and treatment related mortality (TRM) within 100-day of two groups were 0. The partial response(PR) rate after transplantation in BUCY group was significantly decreased (6/20 Vs 0/20, p<0.05), while the patients in the HDM group were not observed this phenomenon. The median PFS of HDM group was 17 months, and the median PFS of BUCY group and median OS of both groups had not been reached yet.
Conclusion
BUCY regimen did not show weakness in safety and survival compared with HDM regimen, which prompt the possibility of BUCY regimen replacing the HDM regimen as the standard regimen in China.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Regimen
Type: Publication Only
Background
Melphalan-based regimen is the standard regimen before autologous stem cell transplantation (ASCT) in the patients with multiple myeloma, but now melphalan is not on the China’s market. There were positive data reported in other researches in terms of safety, response rate and long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Aims
This study retrospectively compare the data in our single center on MM patients with busulfan (BU) and cyclophosphamide(CY) as regimen before ASCT form December to June 2013 to December 2014 with the high-dose melphalan (HDM) regimen. long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Methods
20 cases with BUCY and 17 cases with HDM regimen before ASCT in MM patients were compared in terms of incidence of adverse reaction, the rate of hematopoietic reconstitution, therapeutic effect evaluation and survival.
Results
There is no significant differences between age, gender, duration from diagnosis to transplantation, the type of disease and ISS stage, the number of cycles of induction chemotherapy and disease status before transplantation in the two groups. A 10-day of median myeloid hematopoietic recovery time was observed in both groups, and the median megakaryocyte hematopoiesis reconstruction time was 10-day and 11-day (P > 0.05), respectively, in BUCY and HDM group. The incidence of liver function injury above grade 2 in BUCY group was higher than that in HDM group (30% vs 0, P < 0.05), but there were no hepatic veno occlusive disease (VOD) occurs in both groups. And there was no significant difference in other all regimen toxicity, especially above grade 2 toxicity, and treatment related mortality (TRM) within 100-day of two groups were 0. The partial response(PR) rate after transplantation in BUCY group was significantly decreased (6/20 Vs 0/20, p<0.05), while the patients in the HDM group were not observed this phenomenon. The median PFS of HDM group was 17 months, and the median PFS of BUCY group and median OS of both groups had not been reached yet.
Conclusion
BUCY regimen did not show weakness in safety and survival compared with HDM regimen, which prompt the possibility of BUCY regimen replacing the HDM regimen as the standard regimen in China.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Regimen
Abstract: PB1990
Type: Publication Only
Background
Melphalan-based regimen is the standard regimen before autologous stem cell transplantation (ASCT) in the patients with multiple myeloma, but now melphalan is not on the China’s market. There were positive data reported in other researches in terms of safety, response rate and long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Aims
This study retrospectively compare the data in our single center on MM patients with busulfan (BU) and cyclophosphamide(CY) as regimen before ASCT form December to June 2013 to December 2014 with the high-dose melphalan (HDM) regimen. long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Methods
20 cases with BUCY and 17 cases with HDM regimen before ASCT in MM patients were compared in terms of incidence of adverse reaction, the rate of hematopoietic reconstitution, therapeutic effect evaluation and survival.
Results
There is no significant differences between age, gender, duration from diagnosis to transplantation, the type of disease and ISS stage, the number of cycles of induction chemotherapy and disease status before transplantation in the two groups. A 10-day of median myeloid hematopoietic recovery time was observed in both groups, and the median megakaryocyte hematopoiesis reconstruction time was 10-day and 11-day (P > 0.05), respectively, in BUCY and HDM group. The incidence of liver function injury above grade 2 in BUCY group was higher than that in HDM group (30% vs 0, P < 0.05), but there were no hepatic veno occlusive disease (VOD) occurs in both groups. And there was no significant difference in other all regimen toxicity, especially above grade 2 toxicity, and treatment related mortality (TRM) within 100-day of two groups were 0. The partial response(PR) rate after transplantation in BUCY group was significantly decreased (6/20 Vs 0/20, p<0.05), while the patients in the HDM group were not observed this phenomenon. The median PFS of HDM group was 17 months, and the median PFS of BUCY group and median OS of both groups had not been reached yet.
Conclusion
BUCY regimen did not show weakness in safety and survival compared with HDM regimen, which prompt the possibility of BUCY regimen replacing the HDM regimen as the standard regimen in China.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Regimen
Type: Publication Only
Background
Melphalan-based regimen is the standard regimen before autologous stem cell transplantation (ASCT) in the patients with multiple myeloma, but now melphalan is not on the China’s market. There were positive data reported in other researches in terms of safety, response rate and long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Aims
This study retrospectively compare the data in our single center on MM patients with busulfan (BU) and cyclophosphamide(CY) as regimen before ASCT form December to June 2013 to December 2014 with the high-dose melphalan (HDM) regimen. long-term survival on busulfan combined with other alkylating agents as regimen before ASCT in MM patients.
Methods
20 cases with BUCY and 17 cases with HDM regimen before ASCT in MM patients were compared in terms of incidence of adverse reaction, the rate of hematopoietic reconstitution, therapeutic effect evaluation and survival.
Results
There is no significant differences between age, gender, duration from diagnosis to transplantation, the type of disease and ISS stage, the number of cycles of induction chemotherapy and disease status before transplantation in the two groups. A 10-day of median myeloid hematopoietic recovery time was observed in both groups, and the median megakaryocyte hematopoiesis reconstruction time was 10-day and 11-day (P > 0.05), respectively, in BUCY and HDM group. The incidence of liver function injury above grade 2 in BUCY group was higher than that in HDM group (30% vs 0, P < 0.05), but there were no hepatic veno occlusive disease (VOD) occurs in both groups. And there was no significant difference in other all regimen toxicity, especially above grade 2 toxicity, and treatment related mortality (TRM) within 100-day of two groups were 0. The partial response(PR) rate after transplantation in BUCY group was significantly decreased (6/20 Vs 0/20, p<0.05), while the patients in the HDM group were not observed this phenomenon. The median PFS of HDM group was 17 months, and the median PFS of BUCY group and median OS of both groups had not been reached yet.
Conclusion
BUCY regimen did not show weakness in safety and survival compared with HDM regimen, which prompt the possibility of BUCY regimen replacing the HDM regimen as the standard regimen in China.
Session topic: E-poster
Keyword(s): Autologous hematopoietic stem cell transplantation, Multiple myeloma, Regimen
{{ help_message }}
{{filter}}